After a years-long revenue drought, there's a light at the end of the tunnel. It's been a miserable past three years for Pfizer (PFE 2.42%) shareholders. 2025's projected top line of between $61 billion and $64 billion remains markedly below 2022's record-breaking peak revenue of just over $100 billion. It would also be naïve to ignore that the pharmaceutical company was so focused on COVID-19 that other drug development efforts weren't prioritized at the time. The clearer this company's growth opportunity becomes, however, the higher price you'll pay.